Mirati Therapeutics Inc Net Income per Employee (MRTX), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Mirati Therapeutics Inc   (NASDAQ: MRTX)
 

Mirati Therapeutics Inc Net Income per Employee

MRTX's Quarterly Results, Trends, Rankings, Statistics
Mirati Therapeutics Inc recorded a cumulative net loss of $-726 million during 12 month ending in the third quarter 2023.
The Healthcare sector has seen employees of 361 other companies achieving higher income per employee. While Mirati Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 4255.


What is Income per Employee Ratio?






MRTX Net Income per Employee (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,613,062 -1,638,967 -1,637,927 -1,646,371 -1,640,027
MRTX's Total Ranking # 4255 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


MRTX Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 362
Healthcare Sector # 817
Overall Market # 4255

Net Income per Employee Statistics
High Average Low
$ -93,293 $ -635,963 $ -1,646,371
(Mar 31 2015)   (Dec 31 2022)







Companies with similar Income per Employee for 12 month ending Sep 30 2023, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2023Number of Employees Sep 30 2023


Date modified: 2026-08-29T17:18:11+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.